Vitamin B3 Extends Survival of Lung Cancer Patients by 13 Months by Activating Tumor Suppressor Genes

Research results have been presented suggesting that Vitamin B3 (niacinamide) can extend the survival period of lung cancer patients and suppress recurrence by reactivating tumor suppressor genes. According to a video featuring Professor Bae Seok-cheol on the 'Gyoyukhaneun Uisa! Lee Dong-hwan TV' channel, Vitamin B3 plays a role in inducing cancer cells to die through epigenetic regulation.

Clinical Results of Vitamin B3 Extending Lung Cancer Patient Survival by 13 Months

Professor Bae Seok-cheol explained the anticancer adjuvant effects of Vitamin B3 through the results of a clinical trial conducted on lung cancer patients over seven years starting from 2015. In the video, Professor Bae stated that after receiving clinical trial approval from the Ministry of Food and Drug Safety in 2015, the observation period became longer due to processes such as patient recruitment, which actually led to obtaining unexpected and significant data.

According to the video, when only anticancer drugs were used, the average survival extension period for lung cancer patients was about one year, but when Vitamin B3 was taken together, the survival period was extended by an additional 13 months. This is a very unusual figure compared to the limit of survival extension possible through the use of anticancer drugs alone. Professor Bae explained, "The limit of how much the life of a lung cancer patient can be extended with a single anticancer drug is almost about one year, so extending it by an additional 13 months is a result that exceeds imagination."

The difference in survival rates is particularly noteworthy. When only targeted therapies were used, the survival probability of patients was less than 10%, but when Vitamin B3 was used in combination, the survival probability was maintained at the 40% level. This suggests that Vitamin B3 can increase the survival rate by about 4 to 5 times compared to the use of anticancer drugs alone. Professor Bae mentioned that these results are very surprising in that they appeared through Vitamin B3, which is a natural substance rather than a drug.

Epigenetic Mechanism Awakening the Tumor Suppressor Gene 'LRS3'

The core principle of how Vitamin B3 acts on cancer cells lies in regulating 'epigenetic' changes. The genes in our body exist in an open form and a locked form, and an enzyme called 'Sirtuin' plays the role of locking genes. One of the processes in the occurrence of cancer is that the genes that should suppress cancer are accidentally locked. This phenomenon occurs when the enzyme that locks genes works excessively.

Professor Bae explained that Vitamin B3 strongly inhibits this Sirtuin enzyme, thereby reactivating 'LRS3', the locked tumor suppressor gene. Professor Bae added that he discovered in 2002 that LRS3 is a tumor suppressor gene and presented the principle that it can be reactivated. Previously developed epigenetic regulation drugs were powerful in effect, but they had the limitation of being highly toxic because they unlocked all genes other than the necessary ones. On the other hand, Vitamin B3 is characterized by having a moderate effect but working appropriately only as much as necessary, resulting in fewer side effects. Professor Bae explained, "Vitamin B3 shows an amazing effect of doing exactly as much work as we want."

The Key to Preventing Cancer Recurrence: Inducing the Death of Cells That Must Die

Cancer recurrence occurs because new cancer gene mutations arise in a state where the function of tumor suppressor genes is lost. In our bodies, mutations occur probabilistically with every cell division, and new mutations can appear after about 1 to 2 years. Current targeted therapies focus on inhibiting cancer genes that have mutated, but if the pathway where cells must die themselves (apoptosis pathway) is already blocked, cancer cells do not die and continue to proliferate and recur.

Professor Bae explained that if the tumor suppressor gene LRS3 is reactivated, cells that undergo mutation and divide indiscriminately can be reclassified as 'cells that must die' and removed. This is the principle of making cancer cells undergo apoptosis even if they acquire new mutations. Professor Bae stated, "In the past, cancer recurrence was said to be an unavoidable phenomenon, but it has been proven that treatment without recurrence is possible if tumor suppressor genes are activated." He added that he actually confirmed through animal experiments that when tumor suppressor genes were restored to their original state, cancer was cured and did not recur.